IsraCann Bioscience

IsraCann Bioscience

Israel’s First Pure-Play Cannabis Firm
Business Branding

About IsraCann Bioscience

Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann is fully funded to execute on over 230,000 sq ft of hybrid greenhouse.

The company is targeting undersupplied domestic demand combined with an immense international market opportunity through Israel’s new medical cannabis export framework for 2020.


Mark Zegal
Chairman & Director
Darryl Jones
President & CEO
Israel Moseson

Participation in events